drug-eluting stents

Type 1 Diabetes Confers Double the Risk of Coronary Stent Failure Compared to Non-Diabetics: A SWEDEHEART Analysis

By MedXY 02/02/2026

A nationwide SWEDEHEART study reveals that while second-generation drug-eluting stents have improved outcomes, patients with Type 1 and Type 2 diabetes remain at significantly higher risk for stent failure, with Type 1 patients facing a more than twofold increased risk.

Cardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

By MedXY 01/18/2026

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.

Cardiology news Specialties

Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial

By MedXY 08/13/2025

The CONNECT trial demonstrates no significant difference in neoatherosclerosis rates 3 years post-STEMI between biodegradable and durable polymer everolimus-eluting stents, challenging assumptions about biodegradable polymers' superiority.